Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Salarius subsidiary Decoy Therapeutics’ influenza fusion inhibitors, designed using its proprietary IMP3ACT™ platform, show excellent in silico free energy binding to the viral target entry protein,...
-
HOUSTON and CAMBRIDGE, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) cites an error on the S&P CapIQ platform and reiterates...
-
Salarius Pharmaceuticals and Decoy Therapeutics complete merger
-
Salarius regains compliance with all Nasdaq listing requirements
-
Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
-
HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop...
-
Salarius Pharmaceuticals granted additional extention to regain Nasdaq compliance
-
Phase 1/2 clinical study evaluating seclidemstat in patients with MDS and CMML is progressing with updates expected later this year Company continues to advance its contemplated merger with Decoy...
-
CAMBRIDGE, Mass. and HOUSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide...
-
CAMBRIDGE, Mass. and HOUSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of...